GlassScriptPhysician profile
Nina N Ali
NPI 1447686795
$1,118.24
in general payments reported to CMS, 2019-2025
31 companies · $17.32 in 2025
The $17.32 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $685 · 2022: $265 · 2023: $135 · 2024: $15.52 · 2025: $17.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $168.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $219.92 | 2021-2023 | |
| Novo Nordisk INC | $114.11 | 2021-2022 | |
| Eisai INC. | $77.87 | 2021-2022 | |
| Amarin Pharma, INC. | $59.80 | 2021-2022 | |
| Glaxosmithkline, LLC. | $55.68 | 2021-2024 | Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $55.54 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $51.89 | 2021 | |
| Merck Sharp & Dohme LLC | $45.42 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.99 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.31 | 2021-2023 | Trintellix |
| Amgen INC. | $32.61 | 2021-2025 | Otezla, Repatha |
| Lilly USA, LLC | $31.24 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $20.35 | 2023 | Austedo |
| Bausch Health US, LLC | $19.40 | 2021 | |
| Abbott Laboratories | $19.38 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.38 | 2023 | |
| Boston Scientific Corporation | $18.06 | 2021 | |
| Genentech USA, INC. | $17.71 | 2021 | |
| Antares Pharma, INC. | $16.97 | 2021 | |
| Neurocrine Biosciences, INC. | $16.95 | 2023 | Ingrezza |
| Biohaven Pharmaceutical Holding Company LTD. | $16.19 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.04 | 2022 | |
| Neos Therapeutics, LP | $14.79 | 2023 | Adzenys Xr-Odt |
| Tolmar Pharmaceuticals, INC. | $13.86 | 2021 | |
| Therapeuticsmd, INC. | $13.42 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.75 | 2021 | |
| Dexcom, INC. | $12.63 | 2021 | |
| Amneal Pharmaceuticals LLC | $12.34 | 2021 | |
| Ibsa Pharma INC. | $12.07 | 2022 | |
| Adlon Therapeutics L.P. | $11.05 | 2021 | |
| Dynavax Technologies Corporation | $6.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nina Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.